SCHEMBL167600

SCHEMBL167600

[2H]C([2H])(c1ccnc(N)c1)n1ccc2c(NC(=O)Nc3ccccc3Br)cccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHB4 P54760 1/20 0.39
RAB9A P51151 4/20 0.36
HTT P42858 4/20 0.36
NPC1 O15118 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
LMNA P02545 1/20 0.36
ROCK1 Q13464 1/20 0.36
CXCR1 P25024 1/20 0.35
HCK P08631 1/20 0.35
MAPK12 P53778 1/20 0.35
MAPK14 Q16539 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
CXCR2 P25025 1/20 0.34
THRA P10827 1/20 0.34
THRB P10828 1/20 0.34
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL168670 0.90 MAPT (0.40) HTTMEN1KMT2AROCK1TRPV1
SCHEMBL168209 0.89 KDR (0.37) RAB9AHTTNPC1MEN1KMT2A
SCHEMBL164013 0.89 RAB9A (0.40) RAB9ANPC1MEN1KMT2AROCK1
SCHEMBL166419 0.89 NR1I2 (0.41) EPHB4RAB9AHTTNPC1MEN1
SCHEMBL167501 0.89 DDX3X (0.41) RAB9AHTTNPC1MEN1KMT2A
SCHEMBL167218 0.88 TRPV1 (0.42) EPHB4ROCK1TRPV1KITMAPT
SCHEMBL166951 0.87 FGFR1 (0.36) EPHB4RAB9AHTTNPC1MEN1
SCHEMBL167153 0.86 KDM4E (0.39) RAB9AHTTNPC1LMNAROCK1
SCHEMBL167322 0.86 KDM4E (0.44) MEN1KMT2ALMNAROCK1ALDH1A1
SCHEMBL167481 0.86 MAPT (0.43) MEN1KMT2ALMNAROCK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US claimed
EP-2611806-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS Ascepion Pharmaceuticals, Inc. (CN) 2013-07-10 EP disclosed
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US disclosed
WO-2012028106-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK2, CDK1, CDK3 EPHB4 3126/4885RAB9A 2322/4885HTT 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.